UMU logo

Novo Nordisk Foundation Awards for professors at two Nordic EMBL Partnership nodes

[2017-03-17] Two leading scientists from two Nordic EMBL Partnership sites, DANDRITE (Danish Research Institute of Translational Neuroscience) and MIMS, have both been awarded prestigious prizes and will receive the prizes on a prize ceremony at the Novo Nordisk Headquater in Copenhagen, Denmark, today.

MIMS congratulates two fellow Nordic EMBL Partnership members, Emmanuelle Charpentier and Poul Nissen, who have both been awarded prizes from the Novo Nordisk Foundation. 

The awards

Novo Nordisk Prize: Professor Poul Nissen

Professor Poul Nissen, of the Department of Molecular Biology and Genetics and Interdisciplinary Nanoscience Centre, Aarhus University and Director of the Danish Research Institute of Translational Neuroscience (DANDRITE), the Danish partner of the Nordic EMBL Partnership for Molecular Medicine, has been awarded the Novo Nordisk Prize for his pioneering studies into the structure and function of ion pumps.

 Poul Nissen DANDRITE

These studies also included key contributions of NCMM Group Leader, Jens Preben Morth, from his postdoctoral research.

The Novo Nordisk Prize recognizes unique medical research, or other research contributions, that benefit medical science. The Prize is accompanied by DKK 3 million, awarded by the Novo Nordisk Foundation.

Professor Nissen’s research has primarily harnessed protein crystallography to determine the three-dimensional structure of ion pumps down to the atomic level thereby also explaining the effects of e.g. disease mutations and regulatory interactions. His research has also led to the setting up of companies and industry collaborations.

Read more about the award and Professor Nissen’s research on the following websites:

Novozymes Prize: Professor Emmanuelle Charpentier

150722 Emmanuelle Portrait DSC 4221 bright color crop 1Professor Emmanuelle Charpentier, Director of the Department of Regulation in Infection Biology at the Max Planck Institute for Infection Biology in Berlin, Germany and Visiting Professor and Group Leader at MIMS, has been awarded the 2017 Novozymes Prize for her pioneering research on the CRISPR-Cas9 technology. She receives the prize together with Professor Virginijus Siksnys of Vilnius University in Lithuania. 

Professor Charpentier performed research that led to the development of the CRISPR-Cas9 technology, during her time as a group leader at the MIMS and Umeå University. This ground-breaking gene-editing tool has enabled researchers to precisely and efficiently edit genes in various organisms and cell types, including bacteria, plants and human cells.

The Novozymes Prize recognizes pioneering research, or a technological contribution, that benefits the development and advancement of biotechnology science. This is the first time that two researchers have shared the Prize, which is accompanied by DKK 3 million.

Professor Charpentier will give her 2017 Novozymes Prize Institutional Lecture at MIMS, Umeå University, Sweden, on March 27.

 

Read more about the award and Emmanuelle Charpentier’s research on the following websites:

The two Novo Nordisk Foundation Prizes will be presented in a special ceremony on Friday 17 March. Find out more about the Novo Nordisk Foundation

Research collaborations and the Nordic EMBL

These Novo Nordisk Foundation awards are awarded to two representatives from the Nordic EMBL Partnership nodes, who have been able to draw on the support, expertise and resources of a wide and collaborative research network.

The awards are also a warm recognition by the Novo Nordisk Foundation of the Nordic EMBL Partnership and its importance for original, ground-breaking research across the Nordic region.

About the Nordic EMBL Partnership

The Nordic EMBL Partnership for Molecular Medicine facilitates scientific collaboration across the Nordic region. The Partnership helps to capitalise on both intellectual and material resources within the Nordic region and to exploit emerging technologies and develop molecular and translational medicine.

The Nordic EMBL Partnership for Molecular Medicine was established in 2007 between the EMBL and the universities of Helsinki (Institute for Molecular Medicine Finland - FIMM), Umeå (Laboratory for Molecular Infection Medicine Sweden- MIMS) and Oslo (Centre for Molecular Medicine Norway - NCMM). A Danish node, based at Aarhus University (Danish Research Institute of Translational Neuroscience- DANDRITE) joined the Partnership in 2013.

(Text: Annabel Darby, Communication Officer The Nordic EMBL Partnership for Molecular Medicine)

Photos:

Professor Poul Nissen at the Nordic Partnership Meeting in Umeå 2014, by Eva-Maria Diehl
Professor Emmanuelle Charpentiier, by Hallbauer & Fioretti

Emmanuelle Charpentier about MIMS (2015):
“A sense of high-level education and high-level research, a respect for excellent research, an understanding of support for basic research, for long—term training of PhD students and understanding that good research also comes with time, good working conditions, a sense of community joining forces and reduced administrative burden, respect for junior scientists.” 

news
Emmanuelle Charpentier on YouTube

Postdoc 2016

button Molbiol
NDPIA logo

footer all slides 2014-02-06